Question 1

What is the catalog number for SIRPA Polyclonal Antibody?

Accepted Answer

The catalog number for SIRPA Polyclonal Antibody is A70549-100.

Question 2

What sizes are available for SIRPA Polyclonal Antibody?

Accepted Answer

SIRPA Polyclonal Antibody is available in the following size(s): 100 µL.

Question 3

Is SIRPA Polyclonal Antibody in stock?

Accepted Answer

SIRPA Polyclonal Antibody is currently made to order / not held in immediate stock. Contact us for lead time.

Question 4

Who manufactures SIRPA Polyclonal Antibody?

Accepted Answer

SIRPA Polyclonal Antibody is manufactured by EpiGentek.

Question 5

What is the estimated delivery time for SIRPA Polyclonal Antibody?

Accepted Answer

Estimated delivery time for SIRPA Polyclonal Antibody is approximately 10 business day(s), depending on your location.

Question 6

Is this product species cross-reactive?

Accepted Answer

Cross-reactivity data, based on available testing, is listed under the reactivity section of the datasheet. Contact us if you need reactivity confirmed for a species not listed.

Question 7

Is there an additional fee for hazardous or dry ice shipping of this product?

Accepted Answer

Yes, if this product requires dry ice or is classed as hazardous for transport, the additional fee will be explicitly shown in your quotation before you confirm the order, so there are no surprise charges later.

Question 8

How many freeze-thaw cycles can this product tolerate?

Accepted Answer

We recommend aliquoting the product upon receipt to avoid repeated freeze-thaw cycles, which can reduce activity and stability. This is your responsibility once the product has been delivered.

SIRPA Polyclonal Antibody

Product Specifications

Frequently Asked Questions

Explore Other Products

Frozen Tissue Sections, Lung

2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)acetaldehyde

NARS2 Mouse Monoclonal Antibody [Clone ID: OTI10G5]

Frozen Tissue Blocks, Thyroid gland

PE Anti-Human CD28 Antibody[CD28.2]

PE Anti-Human CD28 Antibody[CD28.2]